Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

BACKGROUND: Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative breast cancer (TNBC), we sought to determine the antitumor effects of selinexor in vitro and in vivo. METHODS: Twenty-six breast...

Descripción completa

Detalles Bibliográficos
Autores principales: Arango, Natalia Paez, Yuca, Erkan, Zhao, Ming, Evans, Kurt W., Scott, Stephen, Kim, Charissa, Gonzalez-Angulo, Ana Maria, Janku, Filip, Ueno, Naoto T., Tripathy, Debu, Akcakanat, Argun, Naing, Aung, Meric-Bernstam, Funda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557476/
https://www.ncbi.nlm.nih.gov/pubmed/28810913
http://dx.doi.org/10.1186/s13058-017-0878-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557476/
https://www.ncbi.nlm.nih.gov/pubmed/28810913
http://dx.doi.org/10.1186/s13058-017-0878-6

Ejemplares similares